CAR-T-19(Immunotech Biopharm)

N/A

Report date: 2025/07/04 17:14:13

Base Information

Drug NameCAR-T-19(Immunotech Biopharm)
Drug Alias NameCAR-T-19(Immunotech Biopharm)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19T lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, B-CellLymphomaPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesImmunotech Applied Science Ltd
China Registration ClassN/A

Develop Information

Active CompaniesImmunotech Biopharm LtdImmunotech Applied Science Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLymphomaPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A